Associations between paraclinical parameters, symptoms and quality of life in patients with acromegaly: a cross sectional study

• Published in: Journal of patient-reported outcomes Vol. 6; no. 1; p. 130
• Main Authors: Gliga, Maximilian Cosma, Reti, Zsuzsanna, Gliga, Camelia, Pascanu, Ionela Maria
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 28.12.2022; Springer Nature B.V; SpringerOpen
• Subjects: Acromegaly; Cross-sectional studies; Disease control; Medicine; Medicine & Public Health; Patient reported outcome; Pituitary; Quality of life; Quality of Life Research; Symptoms; Acromegaly; Patient reported outcome; Pituitary; Symptoms; Quality of life
• ISSN: 2509-8020; 2509-8020
• DOI: 10.1186/s41687-022-00537-9

Introduction Acromegaly is a rare chronic endocrine disorder that can lead to significant quality of life (QoL) impairment and persistent symptomatology in both biochemically uncontrolled as well as in cured or controlled patients. We aimed to conduct an observational cross-sectional study investigating the associations between biochemical disease control, associated comorbidities, and symptoms severity on QoL in a cohort of acromegalic patients. Methods Thirty-one patients with acromegaly were enrolled in our study. AcroQoL and PASQ (Pain assessed acromegaly symptoms questionnaire) questionnaires were applied to all patients. Information about disease status, associated comorbidities, and other relevant clinical and paraclinical data were gathered. Results Patients with uncontrolled acromegaly presented worse QoL and symptoms scores than controlled patients, but the difference was not statistically significant (AcroQoL 57.22 vs 64.04, p  > 0.05; PASQ 12 vs 16.47, p  > 0.05). Worse symptoms were significantly associated with impaired QoL (overall symptoms score on PASQ was negatively correlated with AcroQoL total score, r  = − 0.61, p  < 0.05). Cardiovascular complications were associated with lower QoL scores, but not with worse symptoms (AcroQoL total score in patients with- versus patients without cardiovascular complications: 54.89 vs 70.14, p  < 0.05). Conclusions Achieving biochemical control of acromegaly might not be enough to reverse the QoL impairment and improve symptomatology in acromegalic patients. While symptoms severity and the presence of cardiovascular complications seem to play an important role in reducing patients QoL, the roles of disease control, diabetes, and pituitary insufficiency are less clear.